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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
pramipexole (Mirapex) is a safe and effective drug to treat depression in patients with
mild to moderate Parkinson’s Disease (PD).
Study Design: Review of three English language primary randomized controlled trials
and one randomized prospective, observational study published between 2003-2010.
Data Sources: Three randomized controlled trials and one randomized prospective,
observational study comparing the efficacy of pramipexole to placebo, sertraline (an
SSRI) and other dopamine agonists (pergolide) in the treatment of PD related depression
symptoms were found using PubMed.
Outcome(s) Measured: Each of the four clinical trials assessed the improvement of
depression in PD patients. In addition, they noted how the improvement in mood would
impact patient's quality of life. Prior to the study, all patients received an evaluation of
the severity of their depressive symptoms in order to get a baseline level; this allowed
researchers to note patient's percent change from baseline. This was done through
objective evaluation, as well as self-reported questionnaires. Patients were evaluated for
disease severity, quality of life, motor functioning, psychopathology, activities of daily
living and depression severity.
Results: Three randomized-controlled trials and one randomized prospective,
observational study were included in this review. Results from each study reveals that
pramipexole is a safe and effective drug to treat depression in mild to moderate PD
patients. Pramipexole was found to be more effective than placebo, similar in efficacy to
pergolide and sertraline, but with less adverse reactions than sertraline. The patients’
quality of life also improved due to the reduction in motor symptoms that pramipexole is
currently FDA approved to treat.
Conclusion: The four clinical trials included in this review have shown that pramipexole
is a safe and effective treatment for depression in PD patients. Pramipexole is currently
not approved for use to treat depression in PD and although initial studies are promising,
further evaluation is necessary. In addition the FDA is currently investigating an
association between pramipexole and increased risk of heart failure.
Key Words: pramipexole; Parkinson’s; depression
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INTRODUCTION
Parkinson’s Disease (PD) is a neuropsychiatric disorder. While the classic presentation of
PD is defined by progressive motor symptoms including rigidity, bradykinesia and resting
tremor, there is also a high prevalence of psychopathological and other non-motor symptoms.
The most common psychopathologic co-morbid condition affecting those with PD is depression.1
The prevalence rate of major depressive disorder in PD is 17% and the rate of clinically
significant depressive symptoms has been reported to be as high as 35 - 45%.1 The precise
relationship of depression to the underlying brain disease still remains to be clarified. 2 It is
thought that the degeneration of dopaminergic neurons in the substantia nigra in PD leads to
dysfunction in not only the motor centers of the basal ganglia, but also of the dopamine driven
pleasure centers of the limbic system. 3 This ultimately leads to anhedonia, the most prominent
symptom of PD related depression. 1
While little data are yet available on the cost effectiveness of pramipexole (Mirapex)
when compared with baseline treatment, depression accounts for approximately 40% of
variability in quality of life scores independent from motor symptoms and has been shown to
lead to a more rapid decline in the health of PD patients resulting in more frequent and costly
hospital stays. 1,3,4 Already PD patients, on average, account for 1.45 times more (95% CI 1.42,
1.48) hospital admissions per year when compared with a group of similar peers without PD. 5
The standard treatment of PD is usually levodopa/carbidopa, combined with adjunctive
medications including COMT inhibitors, MAOB-inhibitors and dopamine agonists. Classically
PD patients with depressive symptoms have been treated with selective serotonin reuptake
inhibitors (SSRI), specifically sertraline, or the tricyclic antidepressants (TCA) desipramine,
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imipramine or nortripyline. 1,2 In cases of treatment resistant or psychotic depression
Electroconvulsive Therapy (ECT) is currently the treatment of choice.
Pramipexole has been shown by Goldberg et al, an independent randomized, double blind
study, to be more well tolerated and significantly more effective than placebo in improving
depressive symptoms in patients with treatment refractory bipolar disorder when used as an addon therapy of mood stabilizers.7 Open label trials have suggested that D2/D3 dopamine receptor
agonists, such as pramipexole, might also be effective in reducing depression in PD patients.1
Pramipexole has a preference for D3 vs. D2 receptors in the prefrontal and orbito-frontal cortical
areas of the brain, which are integral to the etiology of depression.3,6 Also, the addition of
pramipexole to standard PD treatment allows for levodopa dosages to be decreased without
compromising treatment outcomes.1,2,4 Prolonged treatment with high doses of levodopa has
long been associated with the development of dyskinesias and motor fluctuations that greatly
decrease the quality of life for those affected. 5
This paper evaluated three randomized controlled trials and one randomized prospective,
observational study comparing the efficacy of pramipexole to placebo, sertraline (an SSRI) and
other dopamine agonists (pergolide) in the treatment of PD related depression symptoms.
OBJECTIVES
The objective of this selective EBM review is to determine whether or not pramipexole is
safe and effective in reducing depressive symptoms in patients with mild to moderate
Parkinson’s Disease and depression.
METHODS
All four clinical trials utilized for this review were selected because their population
included both male and female patients with mild to moderate PD who were at least 18 years old
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and currently on stable levodopa therapy without symptoms of dementia or severe depression.
The intervention used for these PD patients was the administration of pramipexole titrated to an
optimized therapeutic dose. Barone et al (2010) compared the administration of pramipexole to a
visually matched placebo; Rektorova et al compared pramipexole to another dopamine receptor
agonist, pergolide; Barone et al (2006) compared pramipexole to the SSRI sertraline.1,2,4
Outcomes measured in each study were all patient oriented evidence that matters
(POEMs) and included both self reported and observer rated disease severity measurements,
quality of life, motor functioning, psychopathology, activities of daily living (ADLs) and
depression severity measurements. 3 Three of the studies included are randomized controlled
trials, one of which was double blind and placebo controlled while the other two were open label
but randomized and semi-blind (performed by an independent blinded observer). The fourth
study included is a prospective, observational, open study.
Information obtained for this review was found on PubMed using the following key
words: pramipexole; Parkinson’s; depression. All articles were published in the English language
in peer-reviewed journals between the years 2003 – 2010.
All of the articles were selected based on their relevance and importance of outcomes to
the patient. The three trials included in this review were chosen because they met the following
inclusion criteria: randomized-controlled trials, at least semi-blinded, published after 1996 and
patient oriented evidence that matters (POEM). Other studies were excluded based on the
following criteria: not randomized-controlled trials, disease-oriented evidence (DOE), did not
include the selected patient population, did not exclude patients with dementia, severe PD,
history of psychosis/suicidal ideation, pts currently taking dopamine agonists.
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Table 1: Demographics and Characteristics of included studies
Study

Type

# of
pts
296

Age

Inclusion
Criteria
-M or F
-Idiopathic
PD
-HoenYahr
stage 1-3
-Clinically
relevant
Depression
->5 on
GDS-15
-HAM-D
score >16
-Stable
treatment w.
L-dopa
-No history
of motor
fluctuations
-HoehnYahr
stage 1.5-4

Exclusion Criteria

W/D

Interventions

-Motor fluctuations
-Score of < 24 on
MMSE
-Suicidal depression
or psychotherapy
-Malignant
melanoma

30

Randomized
to receive
PPX or
placebo

-Treatment with
dopamine agonists
-Treatment with
antidepressants
-Hx of psychosis or
suicide attempts
-Cardiovascular
disease

8

Randomized
to receive
PPX or
Sertraline

1

Randomized,
double-blind,
placebocontrolled trial

Barone ,
2006

2

National
multicenter
parallel group
randomized
study

67

64.8 + 8.3

Lemke,
2006

Prospective,
Observational
Study

657

67.7+9.2

-Clinical Dx
of PD
-HoehnYahr stage
2-3

-Psychotic
symptoms
-Moderate to severe
dementia
-CI for PPX

23

PPX added to
L-Dopa
regimen

Rektorova,
2003

Randomized
controlled
Trial

41

59+7.7
PPX

-Idiopathic
PD
-Mild to
moderate
depression
-Stable
treatment
with L-dopa

-Hypersensitivity to
study medications
-Renal or
Cardiovascular
failure
-Pregnancy
-Treatment with
neuroleptics
-Presence of
dementia
-Severe depression
-Current Tx with
dopamine agonists
-Presence of other
psychiatric illness

22

Randomized
to receive
PPX or
Pergolide

Barone ,
2010

>30 yo

63.5+7.5
Pergolide

The statistics used in the studies were 95% confidence intervals (CI), Chi squared (X2),
two sided ANCOVA, mean change from baseline, t-test or non-parametric Wilcoxon test and
Odds Ratio (OR) analyses all converted to p-values.
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OUTCOMES MEASURED
Outcomes measured were based on observer rated scales or self-reported questionnaires.
Disease severity was measured using the Hoehn-Yahr Scale, which ranges from 0-5 (Stage 1=
unilateral symptoms, Stage 5 = restricted to wheelchair or bed if unsupported). 4 Trained
observers rated PD motor and non-motor symptom (psychopathology, depression and ADLs)
severity using the Short-Parkinson’s-Evaluation-Scale (SPES) (range 0-98 with higher values
representing more severe symptoms).4 Anhedonia was assessed with the patient reported SnaithHamilton Pleasure Scale (SHAPS-D) (range 0-14, cut-off score for anhedonia > 3, higher values
represent increasing severity). 4 The presence and severity of clinically relevant depression was
evaluated by trained observers using the 15 item Geriatric-Depression-Scale (GDS-15) (higher
values represent increasing severity), the Montgomery-Asberg Depression Rating Scale
(MADRS) (higher values represent increasing severity), the Hamilton Depression Rating Scale
(HAM-D) and the Beck depression Inventory (BDI). Depressive symptoms were also assessed
using the patient reported Zung subjective Self-Rating Depression Scale. The neurological
examination consisted of an evaluation of motor symptoms, depression and activities of daily
living based on the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS I: item 3
depression; UPDRS II: activities of daily living; UPDRS III: motor examination; UPDRS IV:
complications of therapy). 2
RESULTS
Lemke et al was a prospective, observational open study designed to evaluate the safety
and effectiveness of pramipexole as an add-on therapy to levodopa to treat anhedonia and
depression in PD patients. Based on SHAPS-D scores, the frequency of anhedonia decreased
significantly from 45.7% at baseline to 25.5% at the end of the study (X2 = 94.45, p <0.001).3
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The decrease in mild depression, as measured by SPES depression scores, from 46.6% to 37.6%
(X2 = 214.73, p<0.001) was also statistically significant.3 Anhedonia and depression scores were
significantly correlated (p<0.001).3 Drop-outs due to adverse effects occurred in only 3.5% of
subjects.3 The limiting factor of this study is that 86% of patients included received comedication in the form of classic antidepressant medications including SSRIs and TCAs.3 As a
result other variables may have affected the outcomes of the study.
Barone et al (2010) investigated the efficacy and safety of pramipexole versus placebo in
a randomized, double blind placebo controlled trial. The primary endpoint was a change in BDI
total score along with a secondary path analysis to differentiate between direct effects of
pramipexole on depression and indirect improvement from a reduction in motor symptoms. The
adjusted mean change from baseline in BDI scores among subjects not receiving any other
antidepressant medication was -6.2 for pramipexole and -3.7 for placebo (difference -2.5, 95%
CI -4.1 to -0.8; p = 0.004.1 The adjusted mean change from baseline in GDS-15 scores was -2.5
for pramipexole and -1.7 for placebo (difference -0.8, 95% CI -1.5 to -0.1; p=0.035).1 Based on
the results of a path analysis of the total effect of treatment with pramipexole (path coefficient 1.87), 80% (-1.49) of the effect of treatment was caused by direct effect on depressive symptoms
and only 20% (-0.38) was caused by pramipexole’s effects on motor function. 1 12 subjects in the
pramipexole group (8%) and 6 in the placebo group (4%) had severe adverse events. The number
needed to harm (NNH) was 25 for severe adverse events. Meaning that for every 25 people
treated with pramipexole, one will have a severe adverse event.
Table 2: BDI Responders
Control event
rate (CER)

Experimental event
rate (EER)

Relative benefit
increase (RBI)

Absolute benefit
increase (ABI)

Number needed to
treat (NNT)

18%

27%

0.5

0.09

12
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Table 3: Comparison between PPX and Placebo: Mean change from baseline
PPX (n=139)
GDS-15
UPDRS part II
UPDRS part III
SHAPS-D
BDI

-2.5
-2.4
-4.4
0.0
-6.2

Placebo
(n=148)
-1.7
-1.2
-2.2
0.0
-3.7

Treatment group
comparison
-0.8
-1.2
-2.2
0.0
-2.5

95% CI

p value

-1.5 to -0.1
-1.9 to-0.4
-3.7 to -0.7
-1 to 0.0
-4.1 to -0.8

0.035
0.003
0.003
0.52
0.004

Rektorova et al compared pramipexole against another dopamine receptor agonist,
pergolide. The two drugs differ in their chemical composition. Pramipexole is a non-ergoline
preparation, while pergolide is an ergoline preparation. 2 As a result, they act differently on
dopamine receptors. A statistically significant decrease in all UPDRS scores was observed in
both the pramipexole and pergolide groups at the 1% significance level. 2 The average Self-rated
subjective Zung scores decreased similarly in both groups at the 1% significance level. In terms
of objective MADRS scores a statistically significant decrease was seen only in the pramipexole
group at the 5% significance level. This difference was still observed after the effect of motor
improvement (measured by UPDRS III) was controlled for (p =0.036). 2
Table 4: Mean change from baseline, pramipexole vs. pergolide
UPDRS II

UPDRS III

UPDRS IV

Zung

MADRS

pramipexole

-7.6

-16

-2.5

-10.5

-5.83

pergolide

-8.3

-18.0

-2.2

-17.0

-1.19

The rate of MADRS responders (defined as a decrease of >50%) was 44% in the
pramipexole group and 18.7% in the pergolide group. The Number Needed to Treat (NNT) was
four.2 In both groups there was a statistically significant decrease in the daily levodopa dosage:
22% in the pramipexole group and -28% in the pergolide group.2 No statistical significant
difference was noted between the two groups. Both groups were similar in regard to total number
of adverse effects, except for sleep disturbance, which was seen in 4 patients (22%) in the
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pramipexole group and 10 patients (62.5%) in the pergolide group.2 The NNH for all adverse
effects was 17.
Table 5: Treatment effect for MADRS responders
Control Event Rate
(CER)

Experimental Event
Rate (EER)

Relative benefit
increase (RBI)

Absolute benefit
increase (ABI)

Number needed to treat
(NNT)

18.7%

44%

1.35

0.253

4

Barone et al (2006) studied the safety and effectiveness of pramipexole when compared
to an SSRI, sertraline, which is currently commonly used to treat depression in PD patients. The
overall HAM-D score, which evaluated total effect of each drug on depression symptoms,
decreased significantly in both groups. The overall difference was -9.03 + 7.28 for sertraline and
-10.76 + 5.74 for pramipexole.4 Analysis with the Student’s T-test showed that both changes
were highly significant (p<0.001). The rate of complete recovery in the pramipexole group (final
HAM-D score < 8) was 60.6%, significantly higher (p=0.006) than 27.3% in the sertraline
group.4 Based on Chi squared analysis, the rate of HAM-D responders (defined by a decrease of
> 50%) was not significantly different between the two groups (p=0.08).4 Depressive symptoms
in both groups decreased significantly in terms of the self reported Zung scores, from 48.1+7.4 at
baseline to 35.5+10.5 for pramipexole and 49.8+7.7 to 39.3+8.8 for sertraline (both p < 0.0001,
Wilcoxon test). 4 Ancova analysis showed that the difference between groups was not significant
(F = 0.56; p = 0.4586).4 The UPDRS II and III scores decreased in both groups. In both cases,
the change was statistically significant only for the pramipexole group (p<0.05, Wilcoxon test).4
Table 6: mean change from baseline of UPDRS scores
UPDRS II
UPDRS III

Pramipexole
-2.8+3.5
-5.7+8.5

Sertraline
-1.8+4.3
-0.9+7.2
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11 patients in the study reported adverse reactions, all of which were mild or moderate.
Three (9.1%) from the pramipexole group reported dyskinesias, nausea, abdominal pain or
hypothyroidism and eight (24.2%) from the sertraline group reported vertigo, nausea, anxiety,
abdominal pain, asthenia, palpitations, influenza or tremor. No patients withdrew from the
pramipexole group, but five withdrew from sertraline.4 The NNH was 7.
Table 7: Treatment Benefits: HAM-D Recovery
Control Event Rate
(CER)

Experimental Event
Rate (EER)

Relative benefit
increase (RBI)

Absolute benefit
increase (ABI)

Number needed to treat
(NNT)

27.3%

60.6%

1.22

0.33

3

Table 8: Risk of Adverse Reactions
Control Event Rate
(CER)

Experimental Event
Rate (EER)

Relative risk increase
(RRI)

Absolute risk
increase (ARI)

Number needed to
harm (NNH)

24.2%

9.1%

0.624

0.151

7

DISCUSSION
Throughout all the trials, pramipexole proved to be an effective drug to treat depression
in mild to moderate PD patients. In Lemke et al, both the severity and the frequency of
depression as well as anhedonia and motor deficits were reduced significantly following
treatment with pramipexole. This study also showed excellent applicability in that 95.3% of
patients offered the SHAPS-D completed the questionnaire. 3 This study, however, was limited
by its open study design and the fact that it utilized multiple study sites. As a result a selection
bias cannot be excluded.
The study by Barone et al (2010) also showed a substantially higher overall improvement
in depressive symptoms in the pramipexole group over placebo as shown by both the GDS-15
and BDI scores.1 All of the results were modest, possibly due to the mild to moderate initial
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severity of depressive symptoms. Still, there was an overall correlation between the improvement
in depression and an increase in quality of life in the pramipexole group. 1 This study was
enhanced by the exclusion of patients with motor fluctuations.
Rektorova, et al found that the efficacy of pramipexole was similar to that of pergolide
when evaluated using Zung scores, but greater than pergolide when evaluated via MADRS, even
when the effect of motor symptoms was controlled for by data analysis. It is important to note
that only the MADRS and HAM-D are used to diagnose depressive disorder in PD, and as such,
may be considered to be a more reliable instrument than the Zung scale for evaluating
depression.2 When considering the safety of pramipexole versus pergolide there were similar
overall numbers of adverse reactions, but significantly more sleep disturbances in the pergolide
group. A possible limitation of this study is that there was a statistically insignificant difference
between the baseline values of MADRS scores (15.11 for pramipexole, 11.25 for pergolide). 2 It
is possible that the milder initial symptoms in the pergolide group may have added bias by
limiting the potential size of treatment effect. Another limitation is the small number of patients
included in the study, which may affect generalisability.
Barone et al (2006) found that, based on HAM-D scales, both pramipexole and sertaline,
were significantly effective in reducing depressive symptoms in PD patients (p <0.001).4
Pramipexole was, however, significantly more effective in inducing HAM-D recovery (final
score <8) than sertraline. Data analysis also showed that there was no significant correlation
between improvement in motor function and improvement in mood. This suggests that
pramipexole exerted a direct antidepressant effect on study subjects. In terms of safety,
pramipexole proved to be superior to sertraline in terms of the number of adverse events reported
by subjects. Sertraline along with other SSRIs have also been associated with producing a
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reversible parkinsonism in elderly patients taking this class of drugs.4 In patients who already
experience rigidity, bradykinesia and resting tremor these effects are even more unacceptable.
Pramipexole is currently approved for the treatment of idiopathic PD and moderate to
severe Restless Leg Syndrome. It is also used off label for the treatment of resistant bipolar
depression in addition to mood stabilizers.8 There is currently an ongoing safety review in
progress by the FDA regarding the significant risk of heart failure in patients taking pramipexole
(RR: 1.86; 95% CI: 1.21-2.85).8 Pramipexole has also been associated with orthostatic
hypotension, dyskinesias and impulse control problems.8 Therefore, blood pressure and
behavioral monitoring is recommended. The cost of a 30 day supply of pramipexole is
approximately $240 and is covered by most insurance companies and Medicare.8
Pramipexole and all the other drugs studied in the articles included in this review are
already FDA approved and commercially available for use in the United States. Also, none of the
dosages of pramipexole administered in the studies exceeded the approved dose range. Thus, no
new safety risks were anticipated.
CONCLUSION
Pramipexole, a non-ergoline D2/D3 dopamine receptor agonist, was proven to be a safe
and effective treatment for depression in patients with mild to moderate PD. It is similar in
efficacy, if not slightly more effective, than pergolide. In addition, pramipexole, at doses already
utilized for control of motor symptoms, may provide a bonus antidepressant effect without the
risks normally associated with anti-depressant medications. Pramipexole is not currently FDA
approved for the treatment of depression in PD. All of the studies included in this review agree
that further evaluation of pramipexole use as an antidepressant in PD patients is warranted.
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